NA89
NOTICE OF ACCEPTANCE OF SEC. 8 & 9 - E-MAILED
05/08/2026
Back to search
Official data from USPTO
BITE
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
67
Latest update
06/02/2026
Trademark type
Word
Nice classes
5, 35, 42
Filing date
12/26/2000
Registration date
03/14/2006
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
05/08/2026
Last transaction
06/02/2026
Responsible office
United States Patent and Trademark Office
Status code
800
Official register
Principal Register
Filing basis
Intent to use, Foreign priority
First use anywhere
2001-11-00
First use in commerce
2001-11-00
Drawing code
1
Owner type
16
Owner location
MUNICH, DE
Examiner
BLANDU, FLORENTINA
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
AMGEN RESEARCH (MUNICH) GMBH
MICROMET AG
Representatives
Elsa D. Lemoine Amgen Inc.
Technical classification
Nice Classes
Class 5Class 35Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Medicamentspolypeptidesparticularly antibodies and antibody derivativesfor use in the treatment of tumorous diseasesallergiesautoimmunityinflammationinfectious diseasesosteoporosisgraft versus host diseasestransplant rejectioncoronary heart diseasesminimal residual diseasesin the form of intravenoussub-cutaneousintra-peritonealintra-muscular and aerosol therapies
Class 35
Human and veterinary serviceslicensing of medicamentspolypeptidesparticularly antibodies and antibody derivativesfor use in the treatment of tumorous diseasesallergiesautoimmunityinflammationinfectious diseasesosteoporosisgraft versus host diseasetransplant rejectioncoronary heart diseasesminimal residual diseases; licensing of technology for the identification of tumorous diseasesallergiesautoimmunityinflammationinfectious diseasesosteoporosisgraft versus host diseasetransplant rejectioncoronary heart diseasesminimal residual diseasesfor the identification of expressed genesparticularly of abnormal expressed genesfor the analysis and identification of the gene expression pattern and eukaryotic cellsparticularly of single cells and cell culture linesparticularly of mammalian and human cellsparticularly of cells of microscopic small biopsies of animal and human tissuesof cells out of tissue samples prepared with laserof cells isolated with FACS or with receptor to ligand bindingof chemical fixed tissueof micrometastatic cellsof bone marrow cellsof samples of body fluidsparticularly from liquorbloodlymphurine or bowel movementof stem cellscloned single cells or differentiated stages from specific cells
Class 42
Medical services; laboratory research in the field of polypeptidesparticularly antibodies and antibody derivatives; human and veterinary servicesproduct developmentin the field of medicamentspolypeptidesparticularly antibodies and antibody derivativesfor use in the treatment of tumorous diseasesallergiesautoimmunityinflammationinfectious diseasesosteoporosisgraft versus host diseasetransplant rejectioncoronary heart diseases and minimal residual diseases; product developmentin the field of diagnostic and testing apparatus and instruments for the identification of tumorous diseasesallergiesautoimmunityinflammationinfectious diseasesosteoporosisgraft versus host diseasestransplant rejectioncoronary heart diseasesminimal residual diseasesfor the identification of expressed genesparticularly of abnormal expressed genesfor the analysis and identification of the gene expression pattern and eukaryotic cellsparticularly of single cells and cell culture linesparticularly of mammalian and human cellsparticularly of cells of microscopic small biopsies of animal and human tissuesof cells out of tissue samples prepared with laserof cells isolated with FACS or with receptor to ligand bindingof chemical fixed tissueof micrometastatic cellsof bone marrow cellsof samples of body fluidsparticularly from liquorbloodlymphurine or bowel movementof stem cellscloned single cells or differentiated stages from specific cells
Publications
History of USPTO decisions and trademark events.
67 publications found
RNL2
REGISTERED AND RENEWED (SECOND RENEWAL - 10 YRS)
05/08/2026
89AG
REGISTERED - SEC. 8 (10-YR) ACCEPTED/SEC. 9 GRANTED
05/08/2026
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
05/07/2026
E89R
TEAS SECTION 8 & 9 RECEIVED
03/04/2026
REM2
COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED
03/14/2025
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
04/29/2022
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
04/29/2022
EWOR
TEAS WITHDRAWAL AS DOMESTIC REPRESENTATIVE RECEIVED
04/29/2022
EWAF
TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
04/29/2022
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
04/29/2022
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
04/29/2022
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
04/29/2022
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
03/07/2019
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
03/07/2019
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
08/02/2018
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
08/02/2018
NAS8
NOTICE OF ACCEPTANCE OF SEC. 8 - E-MAILED
06/28/2016
RNL1
REGISTERED AND RENEWED (FIRST RENEWAL - 10 YRS)
06/28/2016
9G8P
REGISTERED - SEC. 9 GRANTED/CHECK RECORD FOR SEC. 8
06/28/2016
8PRT
REGISTERED - PARTIAL SEC. 8 (10-YR) ACCEPTED
06/28/2016
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
06/28/2016
E89R
TEAS SECTION 8 & 9 RECEIVED
04/08/2016
ASGN
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
03/23/2016
REM2
COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED
03/14/2015
NA85
NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED
04/02/2012
C15A
REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
04/01/2012
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
03/31/2012
E815
TEAS SECTION 8 & 15 RECEIVED
03/01/2012
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
06/18/2011
R.PR
REGISTERED-PRINCIPAL REGISTER
03/14/2006
REGV
LAW OFFICE REGISTRATION REVIEW COMPLETED
02/01/2006
ALIE
ASSIGNED TO LIE
02/01/2006
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
01/17/2006
SUPC
STATEMENT OF USE PROCESSING COMPLETE
12/27/2005
PAPER RECEIVED
12/05/2005
IUAF
USE AMENDMENT FILED
12/02/2005
EX3G
SOU EXTENSION 3 GRANTED
06/03/2005
EXT3
SOU EXTENSION 3 FILED
05/19/2005
EEXT
SOU TEAS EXTENSION RECEIVED
05/19/2005
EX2G
SOU EXTENSION 2 GRANTED
12/08/2004
EXT2
SOU EXTENSION 2 FILED
11/29/2004
EEXT
SOU TEAS EXTENSION RECEIVED
11/29/2004
EX1G
SOU EXTENSION 1 GRANTED
05/28/2004
CFIT
CASE FILE IN TICRS
05/26/2004
EXT1
SOU EXTENSION 1 FILED
05/19/2004
EEXT
SOU TEAS EXTENSION RECEIVED
05/19/2004
NOAM
NOA MAILED - SOU REQUIRED FROM APPLICANT
12/02/2003
PAPER RECEIVED
09/29/2003
PUBO
PUBLISHED FOR OPPOSITION
09/09/2003
NPUB
NOTICE OF PUBLICATION
08/20/2003
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
06/24/2003
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
05/22/2003
PAPER RECEIVED
05/22/2003
CNRT
NON-FINAL ACTION MAILED
01/06/2003
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
10/21/2002
PAPER RECEIVED
10/21/2002
CNRT
NON-FINAL ACTION MAILED
06/26/2002
ZZZX
PREVIOUS ALLOWANCE COUNT WITHDRAWN
06/09/2002
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
04/10/2002
ZZZX
PREVIOUS ALLOWANCE COUNT WITHDRAWN
04/10/2002
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
02/14/2002
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
02/05/2002
CNEA
EXAMINERS AMENDMENT MAILED
02/04/2002
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
11/29/2001
CNRT
NON-FINAL ACTION MAILED
06/06/2001
DOCK
ASSIGNED TO EXAMINER
05/17/2001
Continuous trademark protection
Get notified about every new filing that threatens BITE or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.